According to trial CA209037, the objective response rate (ORR) in the PDL-1 positive was 43.6%, 20.3% in PDL-1 negative patients, 23.1% in those patients who have BRAF V600 mutation-positive melanoma, and 34% in BRAF wild-type melanoma. Here, CD274 is linked to melanoma.